- Home
- PDI vs LEGN Comparison
PDI vs LEGN Comparison
Compare PDI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDI | LEGN |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PDI | LEGN |
|---|---|---|
| Price | $15.27 | $19.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $61.33 |
| AVG Volume (30 Days) | ★ 3.8M | 1.7M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.88 | $16.24 |
| 52 Week High | $19.96 | $37.50 |
Technical Indicators
Market Signals| Indicator | PDI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 41.68 |
| Support Level | $15.08 | $19.96 |
| Resistance Level | $15.57 | $20.39 |
| Average True Range (ATR) | 0.20 | 0.99 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 57.25 | 7.47 |
Price Performance
Historical ComparisonAbout PDI PIMCO Dynamic Income Fund
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investment portfolio includes mortgage-backed securities, investment-grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.